RE:News Release!Yes, a great summary of where we stand. Any investor reading this and conducting further DD on this company would have to be impressed. How many others out there have guaranteed revenue over the next year and a blockbuster technoloy 20 years in the making about to be unleashed anyday.
The likes of Ichor/Mercer will be looking to replace the covid nasal swab collection process with something else as Covid slows down - Aristotle and the blood draw requirement for it will be a natural fit and many Covid customers will undoubtedly take a look. These are exciting times as we await that rollout and additional collaborations will be more icing on the cake. GLTA!